RMGP Biopharma Investment Fund is focused on early stage innovative therapies in areas of high unmet need. Through its partnership with OrbiMed, Johnson & Johnson and Takeda, RMGP provides an opportunity to invest in the cutting-edge portfolio of the FutuRx incubator. The RMGP Biopharma Investment Fund is managed by RM Global Healthcare Fund Management.
FutuRx is a biotechnology incubator based on novel science developed world-wide, with a unique model for transforming breakthrough discoveries into novel medicines.
RMGP Biopharma Investment Management and its partners identified FutuRx’s innovative early-stage biopharma portfolio as a highly attractive investment opportunity.
OrbiMed, Johnson & Johnson and Takeda together with the Israel Innovation Authority founded FutuRx, a biotechnology incubator that serves as a launchpad for biopharma startups.
Highly innovative portfolio of novel first-in-class or best-in-class biopharma assets, for the benefit of patients and healthcare providers, being developed in the FutuRx incubator.